Activity-based CO₂ sensing using CarboSenR2 provides new insights into cellular metabolism
Reddan, B., Shahen, R., Radi, R., McCalmont, M., Green, O. and Cummins, E.P., 2026. Redox Biology, p.104067.
Pioneering next-generation solutions for mitochondrial therapeutic development.

Mitochondria are core to human biology. Beyond producing the energy that powers every cell, they play essential roles in metabolism, cellular signaling, immune function, and the regulation of cell survival. When mitochondrial function is disrupted, the consequences extend across multiple organ systems and are implicated in a growing number of diseases.
We are advancing the field through technological innovation. We develop next-generation platforms and enabling technologies that accelerate mitochondrial therapeutic discovery and development. By combining cutting-edge science with engineering and translational expertise, we empower researchers and drug developers to better understand mitochondrial function, identify novel therapeutic opportunities, and bring transformative medicines closer to patients.
Next-generation platforms that enable smarter drug discovery, deeper biological insight, and earlier prediction of mitochondrial toxicity.
Advanced technologies, data collection and monitoring, and end-to-end discovery support.
Explore capabilities →Research partnerships, screening services, toxicity profiling and platform licensing.
See how we partner →A direct, live, functional readout of mitochondrial activity in living cells.
Discover TCAFlux™ →Mitochondria play a central role in cellular energy production, metabolic regulation and cell survival. Drug-induced mitochondrial dysfunction has been associated with adverse effects, drug withdrawals and attrition during drug development.
A 2023 review highlighted the association between mitochondrial effects and almost half of FDA black-box warnings, underlining the importance of understanding mitochondrial liabilities during drug development.
Hoogstraten, C.A., Lyon, J.J., Smeitink, J.A., Russel, F.G. and Schirris, T.J., 2023. Time to change: a systems pharmacology approach to disentangle mechanisms of drug-induced mitochondrial toxicity. Pharmacological Reviews, 75(3), pp.463-486.
A study evaluating 228 pharmaceutical compounds demonstrated that the performance of in-vitro mitochondrial toxicity assays can vary considerably depending on the organ-specific toxicity endpoint being investigated. Reported assay sensitivities differed for liver, cardiac and kidney toxicity, highlighting the complexity of identifying drug-induced mitochondrial liabilities.
Mitochondrial toxicity is multifaceted. Combining complementary functional assays can help researchers investigate compound-induced effects, characterise potential liabilities and build a more comprehensive picture of mitochondrial dysfunction.
Rana, P., Aleo, M.D., Gosink, M. and Will, Y., 2019. Evaluation of in vitro mitochondrial toxicity assays and physicochemical properties for prediction of organ toxicity using 228 pharmaceutical drugs. Chemical Research in Toxicology, 32(1), pp.156-167.
A compound may alter mitochondrial metabolism before overt loss of cell viability becomes apparent. Combining complementary functional readouts can help researchers investigate these changes and build a more complete picture of compound effects.
Reddan, B., Shahen, R., Radi, R., McCalmont, M., Green, O. and Cummins, E.P., 2026. Redox Biology, p.104067.
Green, O., Finkelstein, P., Rivero-Crespo, M.A., Lutz, M.D., Bogdos, M.K., Burger, M., Leroux, J.C. and Morandi, B., 2022. Journal of the American Chemical Society, 144(19), pp.8717-8724.
Whether you have a question, an idea, or just want to say hello, feel free to reach out. We are here to help.